BEVERLY, Mass.-- American Renal Associates Holdings, Inc. (“ARA”) today announced the pricing of its initial public offering of 7,500,000 shares of common stock at an initial public offering price of $22.00 per share. ARA has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price. ARA’s common stock is expected to begin trading on the New York Stock Exchange under the ticker symbol “ARA” on April 21, 2016. The offering is expected to close on April 26, 2016, subject to customary closing conditions.
BofA Merrill Lynch, Barclays and Goldman, Sachs & Co. are serving as lead joint book-running managers and as representatives of the underwriters for the offering. Wells Fargo Securities, LLC and SunTrust Robinson Humphrey are acting as joint book-running managers. Leerink Partners is acting as co-manager.
A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission on April 20, 2016. The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email: email@example.com, Barclays Capital Inc., c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, email: Barclaysprospectus@broadridge.com or Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, email: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About American Renal Associates
As of December 31, 2015, American Renal Associates Holdings, Inc. (ARA) operated 192 dialysis clinic locations in 24 states and the District of Columbia, treating over 13,000 patients with end stage renal disease. ARA operates exclusively through a physician joint venture model, in which it partners with 347 local nephrologists to develop, own and operate dialysis clinics.
Darren Lehrich, SVP Strategy & Investor Relations